Clinical trial · Observational
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer
NCT04854590CI-TRIAL-00079095completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Small Cell | Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of febrile neutropenia (yes/no) and by severity (CTCAE grade)
- timeFrame
- 16weeks
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: -Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide. Exclusion Criteria: -Patients who have no treatment history with the product (i.e.,durvalumab)
References
Publications (0)
Data not yet available
No reference posted for this study.